Case-control studycited by the Tayebat archiveabstract only checked A-ODD-14 standard review
GLP-1 drugs and pancreatitis in US claims
Glucagonlike peptide 1-based therapies and risk of hospitalization for acute pancreatitis in type 2 diabetes mellitus: a population-based matched case-control study.
Overview
Singh S et al.. JAMA Intern Med 2013 · PMID 23440284 · DOI 10.1001/jamainternmed.2013.2720
Users had about twice the odds of pancreatitis, but they also had more risk factors.
Does the study support the specific claim? Partly · Methodological quality: low
Plain-language summary
Study explained simply
- What did the researchers want to find out?
GLP-1-based therapies and acute pancreatitis
- How was the study done?
Population-based matched case-control (US claims)
- How many people, animals or samples were studied?
1,269 cases, 1,269 controls; Adults 18-64 with type 2 diabetes
- What was actually found?
aOR 2.24.
- How large was the observed effect?
aOR 2.24 (1.36-3.68)
- What do the results mean in everyday life?
Signal not confirmed in trials.
- What are the study's limitations?
Strong confounding; Claims data
- What does it say about Elawady's specific claim?
Supports C-ODD-04.
- Do the results apply to Germany and Europe?
US data.
- What can explicitly not be concluded from this study?
Causation.
Scientific in-depth review
1. Full reference
- Authors
- Singh S, Chang HY, Richards TM, Weiner JP, Clark JM, Segal JB
- Journal
- JAMA Intern Med
- Year
- 2013
- Identifier
- PMID 23440284 DOI 10.1001/jamainternmed.2013.2720
- Verification
- verified – PubMed E-utilities efetch, 2026-10-25
- Retracted
- no
- Corrections
- none
- Extent checked
- abstract only
- Conflicts of interest and funding
not stated in abstract; grants: NCRR NIH HHS
2. Research question
GLP-1-based therapies and acute pancreatitis
3. Study design and population
- Study design
- Case-control study – Population-based matched case-control (US claims)
- Population
Adults 18-64 with type 2 diabetes
- Country
USA
- Period
2005-2008
- Sample size
1,269 cases, 1,269 controls
- Inclusion and exclusion criteria
As described in the abstract; details not available in abstract.
4. Methods and endpoints
- Exposure / intervention
Exenatide or sitagliptin
- Comparator
Non-users
- Endpoints
Hospitalisation for acute pancreatitis
- Statistical methods
Conditional logistic regression
5. Actual results
- Results
Cases had more hypertriglyceridaemia, alcohol use, gallstones, smoking, obesity. Current use aOR 2.24 (1.36-3.68); recent use aOR 2.01 (1.37-3.18).
- Absolute risks
not reported
- Authors' conclusion
GLP-1-based therapies associated with increased odds of hospitalisation for acute pancreatitis.
6. Strengths
- Validated case algorithm
7. Weaknesses
- Strong confounding
- Claims data
8. Risk of bias
- Orienting tool
- ROBINS-E
- Type of assessment
- simplified assessment (abstract only)
- Full formal assessment
- no
- Overall risk of bias
- high
- Rationale
Imbalanced risk factors.
9. Assessment of the statistical interpretation
Association; not confirmed by RCT MA.
10. Relevance to the specific claim
Supports C-ODD-04.
11. Independent contrary findings
12. Transferability to Germany and Europe
US data.
13. Overall methodological judgement
Unconfirmed signal.
| Multidimensional assessment | |
|---|---|
| Authenticity of the source | verified |
| Methodological quality | low |
| Risk of bias | high |
| Precision of results | low |
| Directness | direct |
| Reproducibility | not replicated |
| Consistency with the overall evidence | inconsistent |
| Regional transferability | high |
| Adequacy of the interpretation (by the archive) | essentially correct but incomplete |
14. Open questions
None beyond those stated.
15. Linked fact checks
- Injectable diabetes and weight-loss drugs (GLP-1 receptor agonists) can trigger pancreatitis and cysts. – Studies supporting the claim
- Every major class of glucose-lowering drug (metformin, sulfonylureas, thiazolidinediones, DPP-4 inhibitors, SGLT2 inhibitors, GLP-1 agonists) carries a documented signal of serious harm in the peer-reviewed literature. – Studies supporting the claim
Use by the Tayebat archive
Note: according to the archive, the studies were compiled by the archive operators. Whether Dr. Elawady himself cited this study is not established.
- What the archive says about the study
Listed in the archive bibliography for 'oral-diabetes-drugs' without its own interpretation; used as support for the claim that every drug class carries documented harm.
- A. What was actually studied?
GLP-1-based therapies and acute pancreatitis
- B. What did the authors find?
aOR 2.24.
- C. What conclusions do the authors themselves draw?
GLP-1-based therapies associated with increased odds of hospitalisation for acute pancreatitis.
- D. What does the archive derive from it?
Support for pancreatitis claim in the archive quote.
- E. Is this derivation scientifically justified?
Partly; RCT meta-analysis (I-ODD-11) did not confirm.
- Adequacy of the interpretation (by the archive)
- essentially correct but incomplete